GYRE
Gyre Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$6.86
+6.52%Margins
Gross margin
94.3%
EBITDA margin
-11.7%
EBIT margin
-14.0%
Net margin
-14.5%
FCF margin
-14.1%
-13.3%
Return on equity
-8.7%
Return on assets
-12.5%
Return on invested capital
0.66x
Asset turnover
-$14.5M
Cash from operations
$0.71
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Jun 1, 2026